Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in SPRY held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 10.9M | $87.0M | 0.0% | 10.937% | 0.76% |
| 2 | Rubric Capital Management LP | 8.5M | $68.4M | +6.8% | 8.601% | 0.63% |
| 3 | ORBIMED ADVISORS LLC | 8.3M | $66.4M | 0.0% | 8.347% | 1.23% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 7.5M | $60.1M | 0.0% | 7.556% | 0.63% |
| 5 | BlackRock, Inc. | 5.3M | $42.5M | +6.0% | 5.349% | 0.00% |
| 6 | Tyro Capital Management LLC | 4.5M | $35.7M | +50.2% | 4.491% | 8.01% |
| 7 | Aberdeen Group plc | 4.2M | $33.4M | +1.4% | 4.200% | 0.05% |
| 8 | SR ONE CAPITAL MANAGEMENT, LP | 4.0M | $32.1M | 0.0% | 4.041% | 3.09% |
| 9 | STATE STREET CORP | 3.7M | $29.9M | +2.4% | 3.757% | 0.00% |
| 10 | Capital World Investors | 2.8M | $22.1M | — | 2.774% | 0.00% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $20.5M | +0.4% | 2.571% | 0.00% |
| 12 | MILLENNIUM MANAGEMENT LLC | 2.5M | $20.2M | -57.9% | 2.539% | 0.01% |
| 13 | UBS Group AG | 1.9M | $15.5M | -14.2% | 1.953% | 0.00% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $13.6M | +11.3% | 1.711% | 0.00% |
| 15 | BOOTHBAY FUND MANAGEMENT, LLC | 1.6M | $12.8M | +539.1% | 1.613% | 0.17% |
| 16 | GENERAL AMERICAN INVESTORS CO INC | 1.1M | $9.1M | +55.8% | 1.141% | 0.54% |
| 17 | Third Point LLC | 1.0M | $8.0M | 0.0% | 1.007% | 0.17% |
| 18 | PEREGRINE CAPITAL MANAGEMENT LLC | 672K | $5.4M | — | 0.677% | 0.17% |
| 19 | Tejara Capital Ltd | 607K | $4.9M | +188.5% | 0.611% | 2.00% |
| 20 | ADAR1 Capital Management, LLC | 601K | $4.8M | -55.9% | 0.605% | 0.22% |
| 21 | Pavaki Capital Management LLC | 580K | $4.6M | — | 0.584% | 0.70% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 567K | $4.5M | +11.0% | 0.571% | 0.00% |
| 23 | CITADEL ADVISORS LLC | 567K | $4.5M | -69.2% | 0.571% | 0.00% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 551K | $4.4M | +3.4% | 0.555% | 0.00% |
| 25 | NORTHERN TRUST CORP | 549K | $4.4M | +3.7% | 0.553% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SPRY — a direct measure of their conviction.
Filings activity in SPRY during Q2 2026, grouped by how each filer changed its position.
Institutions that opened a new SPRY position in Q2 2026
Institutions that fully closed their SPRY position in Q2 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 206 | +1.5% | 91.44% | 2.93 pp | $709M | 3.6% |
| Q1 2026 | 203 | +6.8% | 94.37% | +4.12 pp | $735M | 28% |
| Q4 2025 | 190 | +0.5% | 90.25% | +3.60 pp | $1.02B | +21% |
| Q3 2025 | 189 | +1.1% | 86.65% | +0.64 pp | $844M | 42% |
| Q2 2025 | 187 | +2.2% | 86.01% | +9.50 pp | $1.45B | +57% |
| Q1 2025 | 183 | +13% | 76.51% | +4.26 pp | $927M | +25% |
| Q4 2024 | 162 | +10% | 72.25% | +5.84 pp | $741M | 19% |
| Q3 2024 | 147 | — | 66.41% | — | $912M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying SPRY stock.
Based on Q2 2026 13F filings, institutional ownership of ARS Pharmaceuticals, Inc. stands at 91.4%, held across 206 reporting institutions.
RA CAPITAL MANAGEMENT, L.P. is the largest reported institutional holder of SPRY, with approximately 10,860,977 shares worth $0.09B as of Q2 2026.
Yes — 3 widely-followed marquee investors appear among the top 25 institutional holders of SPRY, including MILLENNIUM MANAGEMENT LLC, Third Point LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for SPRY is 52 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
34 institutions opened new positions in SPRY during Q2 2026, while 31 fully exited. 70 added to existing positions and 91 trimmed.
SPRY institutional ownership fell by 2.93 percentage points quarter-over-quarter, with a net change of +3 holders.
The top 10 institutions account for 67.4% of all reported 13F value in SPRY, and the top 25 account for 86.8%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.